Overview of This Research:
The study involved two major activities in estimating the current market size of the human microbiome market. Exhaustive research was conducted to collect information on the market as well as its peer and parent markets. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation were used to estimate the market size of segments and subsegments.
Expected Revenue Growth:
The global human microbiome market is projected to reach USD 1,731 million in 2027 from USD 942 million in 2024, at CAGR of 22.5 % during the forecast period
Major Growth Boosters:
Market growth is largely driven by the increasing focus on the development of human microbiome therapy. It has also become a validated target for drug development. The growing number of collaborations between market players is expected to offer a wide range of growth opportunities for market players during the forecast period. However, a lack of expertise and detailed research on the human microbiome is restraining the growth of this market.
Download PDF Brochure@
The therapeutics segment to account for the largest share of the market in 2022
Based on application, the human microbiome market is segmented into therapeutics and diagnostics. The therapeutics segment is expected to dominate the market in 2022. This is due to the need for the development of reliable, precise, and quicker treatment of chronic lifestyle diseases and various other disorders.
The probiotics segment to account for the largest share of the global human microbiome market in 2022
Based on product, the human microbiome market is segmented into probiotics, prebiotics, foods, medical foods, diagnostic tests, and drugs. The probiotics segment is expected to account for the largest share of the human microbiome market in 2022. The increasing awareness of probiotics for the prevention and treatment of various lifestyle & chronic diseases and health benefits of probiotics over conventional medicines, such as antibiotics are some of the major factors driving the growth of this segment.
Key questions addressed by the report:
# Who are the major market players in the human microbiome market?
# What are the regional growth trends and the largest revenue-generating regions for the market?
# W What are the major drivers and challenges in the market?
# What are the major product segments in the market?
# What are the major technologies used in the human microbiome research spending market?
The infectious diseases segment to account for the largest share of the market in 2022
Based on disease, the human microbiome market is segmented into five categories—infectious diseases, endocrine & metabolic disorders, inflammatory diseases, cancer, and other diseases. The infectious disease segment is expected to dominate the market in 2022. This is due to the increasing research in microbiome-based products and their use in treating infectious diseases. Many smaller companies are investing in research, and their major focus is on developing products targeting microbiome modulators for infectious diseases.
Europe to account for the largest share of the human microbiome market in 2022
On the basis of region, the global human microbiome market is segmented into four major geographies— North America, Europe, the Asia Pacific, and the Rest of the World (RoW). Europe is expected to account for the largest share of the global human microbiome market in 2022. The large share of this regional segment is mainly due to the high research activity in this region.
Request Sample Pages@
The ATP assays market is highly consolidated, with a few players competing for a larger market share. The top ten players account for more than half of the total market share, while other global and regional market players account for the remaining share.
Prominent players in this market include Merck KGaA (Germany), Thermo Fisher Scientific, Inc. (US), PerkinElmer, Inc. (US), Lonza Group (Switzerland), Promega Corporation (US), Hygiena, LLC. (US), Agilent Technologies, Inc. (US), Abcam plc. (UK), Danaher Corporation (US), BioThema AB (Sweden), Abnova Corporation (Taiwan), AAT Bioquest (US), PromoCell GmbH (Germany), BioVision, Inc. (US), Biotium (US), Canvax Biotech S.L. (Spain), Creative Bioarray (US), Elabscience (US) and MBL International Corporation (US).
These players adopted various strategies such as partnerships, agreements, mergers, and acquisitions to expand their presence in the global ATP assays market.